Strand Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

<p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_92706a9ee1.png" alt="PatSnap MCP servers used for the Strand Therapeutics BD opportunity scan"></a></p><p><strong>This Strand Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows.</strong> Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. <a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener">Explore the MCP servers used in this report.</a></p><p><em>Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.</em></p><h2>Executive BD thesis</h2><p>Strand Therapeutics is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 8 records at the decision date. The lead returned asset is <strong>STX-001</strong>, associated with IL-12 and Advanced Malignant Solid Neoplasm, BRAF V600E Mutation-Positive Melanoma, Melanoma, Triple Negative Breast Cancer, at Phase 2. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.</p><p>A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.</p><h2>Partnering shortlist</h2><table><thead><tr><th>Priority</th><th>Asset / workstream</th><th>Owner</th><th>Stage</th><th>Evidence package</th><th>IP risk screen</th><th>Deal precedent</th><th>Outreach rationale</th></tr></thead><tbody><tr><td>1</td><td><strong>STX-001</strong></td><td>Strand Therapeutics, Inc.</td><td>Phase 2</td><td>Pipeline record: IL-12; Advanced Malignant Solid Neoplasm, BRAF V600E Mutation-Positive Melanoma, Melanoma, Triple Negative Breast Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Phase 2 asset with IL-12 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>2</td><td><strong>STX-003</strong></td><td>Strand Therapeutics, Inc.</td><td>Preclinical</td><td>Pipeline record: IL-12; Non-Small Cell Lung Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Preclinical asset with IL-12 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>3</td><td><strong>STX-005</strong></td><td>Strand Therapeutics, Inc.</td><td>Preclinical</td><td>Pipeline record: target not returned; Autoimmune Diseases, Hematologic Neoplasms. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Preclinical asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>4</td><td><strong>MQD1-8C</strong></td><td>Strand Therapeutics, Inc.</td><td>Preclinical</td><td>Pipeline record: IGF-1R; Colorectal Cancer. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Preclinical asset with IGF-1R exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>5</td><td><strong>anti-CD19 CAR T-cell therapy ( Strand Therapeutics )</strong></td><td>Strand Therapeutics, Inc.</td><td>Discovery</td><td>Pipeline record: CD19; Non-Hodgkin Lymphoma. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Discovery asset with CD19 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr></tbody></table><p><strong>Shortlist interpretation.</strong> Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_2ed6f2cf76.png" alt="PatSnap Life Sciences MCP workflow for Strand Therapeutics"></a></p><h2>Pipeline and evidence-package readout</h2><p>The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.</p><p>Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.</p><h2>Deal precedents and structure signals</h2><table><thead><tr><th>Date</th><th>Transaction</th><th>Status</th><th>Disclosed economics</th></tr></thead><tbody><tr><td>2021-01-11</td><td>Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology</td><td>Active</td><td>Not disclosed</td></tr></tbody></table><p>Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.</p><h2>Financial capacity and partnering pressure</h2><ul><li><strong>STANDEX INTERNATIONAL CORP/DE/ - 2021 Annual report</strong>: STANDEX INTERNATIONAL CORP/DE/ - 2021 Annual report Scientific Net cash provided by continuing operating activities for the year ended June 30, 2021 was $81.9 million compared to net cash provided by continuing operating activities of $54.7 million in the prior year. We generated $94.7 million from income statement activities and used $4.4 million of cash to fund working capital decreases. Cash flow used in investing activities for the year ended June 30, 2021 totaled $39.1 million. Uses of investing cash consisted primarily of $27.4 million for the acquisition of Renco and capital expenditures of $21.8 million offset by $11.7 million of proceeds from sale of the Engineticsfi business. Cash used by financing activities for the year ended June 30, 2021 were $31.7 million and included stock repurchases of $21.2 million and cash paid for dividends of $11.4 million. Net cash provided by cont</li><li><strong>OncoTherapy Science, Inc. - Annual securities report-20th Period(2020.04.01-2021.03.31)</strong>: OncoTherapy Science, Inc. - Annual securities report-20th Period(2020.04.01-2021.03.31) ② 创薬研究の确実な推进 なお、研究开発の状况の详细につきましては、「第２ 事业の状况 ５研究开発活动 （２）研究开発活动 （a）「医薬品の研究及び开発」并びにこれらに関连する事业」をご覧ください。 b. がんプレシジョン医疗関连事业 受托検查サービスによる収入等の受领により、事业収益は271百万円（前期比61百万円の増加）となりました。 また、遗伝子解析サービス（全エクソームシーケンス解析、RNAシーケンス解析、ネオアンチゲン解析等）、リ キッドバイオプシー、TCR/BCRレパトア解析、免疫反応解析等の解析サービスに関する研究开発费用及び売上原価 の计上を主な要因として、営业损失は293百万円（前期は393百万円の损失）となりました。 なお、研究开発の状况の详细につきましては、「第２ 事业の状况 ５研究开発活动 （２）研究开発活动 （b）がんプレシジョン医疗関连事业」をご覧ください。 ②キャッシュ・フローの状况 当连结会计年度における现金及び现金同等物（以下「资金」という。）は、2,899百万円（前连结会计年度比 1,814百万円减少）となりました。 当连结会计年度のキャッシュ・フローの概况は以下のとおりです。 （営业活动によるキャッシュ・フロー） 当连结会计年度における営业活动によるキャッシュ・フローは、1,762百万円の资金の减少（前连结会计年度 末は2,275百万円の减少）となりました。これは、税金等调整前当期纯损失1,560百万円を计上したことが主な要 因となっております。 （投资活动によるキャッシュ・フロー）</li><li><strong>Viking Therapeutics, Inc. - 2021 Annual report</strong>: Viking Therapeutics, Inc. - 2021 Annual report Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Results of Operations Comparison of the Years Ended December 31, 2021 and 2020 Research and Development Expenses The following table summarizes our research and development expenses for the years ended December 31, 2021 and 2020 (in thousands, except % change). $ % Research and development expenses The increase in research and development expenses during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was primarily due to increased expenses related to our clinical studies of $7.2 million, pre-clinical studies of $3.3 million, manufacturing for our drug candidates of $2.2 million, third- party consultants of $291,000 and stock-based compensation of $265,000, partially offset by a dec</li></ul><p>Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.</p><h2>Current-awareness events and outreach triggers</h2><p>The Current Awareness <code>news_search</code> call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.</p><p>The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.</p><h2>IP and freedom-to-operate risk screen</h2><p>The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.</p><p>Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.</p><h2>Recommended deal structures</h2><ul><li><strong>Regional license:</strong> useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.</li><li><strong>Co-development:</strong> appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.</li><li><strong>Option-to-license:</strong> reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.</li><li><strong>Research or platform collaboration:</strong> suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.</li><li><strong>Structured financing:</strong> may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.</li></ul><h2>Outreach rationale and first-contact plan</h2><ol><li><strong>Identify the decision owner.</strong> Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.</li><li><strong>Lead with one verifiable gap.</strong> Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.</li><li><strong>Attach a concise evidence package.</strong> Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.</li><li><strong>Offer a structure.</strong> Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.</li><li><strong>Define the diligence sequence.</strong> Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.</li></ol><h2>Decision memo</h2><p><strong>ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH.</strong> Strand Therapeutics offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.</p><p><strong>Required next diligence:</strong> refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_dddd7a2c83.png" alt="Explore PatSnap MCP servers for Strand Therapeutics partnering intelligence"></a></p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><strong>Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.</strong></a></p><hr><p><strong>Data provenance:</strong> PatSnap Company & Deal Intelligence MCP (<code>organization_pipeline_fetch</code>, <code>drug_deal_search</code>, <code>financial_report_search</code>) and Current Awareness MCP (<code>news_search</code>); accessed 22 July 2026. Counts, ownership and statuses may change as records update.</p>